Promotions & Moves

Fibrocor Therapeutics Appoints First CEO

The company is also currently in talks with large pharma partners regarding its pipeline programs

Fibrocor Therapeutics has appointed Mark Steedman as its first president and chief executive officer. He will also serve as a member of the company’s board of directors.
 

Fibrocor is focused on developing disease modifying therapeutics in fibrosis. Using a first-in class tissue discovery platform, Fibrocor has partnered with Evotec and MI to develop treatments to novel molecular targets and pathways in fibrosis.


Mr. Steedman is the co-founder of Interface Biologics where he most recently served as vice president of Business Development. His responsibilities there included all start-up operations including financing, which led to a Series A round totaling $13 million.

 

“We are extremely pleased to be able to recruit an executive with such extensive knowledge and background in life sciences venture-building” said Rafi Hofstein, president and chief executive officer of MI.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters